Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioTheranostics, Inc.
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
The new-generation of tests from Myriad and NanoString have outperformed Genomic Health's Oncotype Dx in predicting which breast cancer patients are at low-risk for a recurrence in five to ten years, and therefore do not need to be on extended endocrine therapy.
Roche's diabetes business continues to struggle as third quarter results show sales in the division dipped by 3%, while Quest Diagnostics' bottom line took a hit from special charges. Meanwhile, bioMérieux said third-quarter revenues increased by 7%; Danaher is finalizing its acquisition of Cepheid.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing